<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581814</url>
  </required_header>
  <id_info>
    <org_study_id>disfunzionale14</org_study_id>
    <nct_id>NCT01581814</nct_id>
  </id_info>
  <brief_title>Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin
      alone and DRSP/EE plus metformin on some cardiovascular risk factors in hyperinsulinemic PCOS
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS), one of the most common endocrine disorders affecting women
      on reproductive age , seems to be associated with an increased incidence of cardiovascular
      disease. At present, insulin-sensitizing drugs, such as metformin, represent one of the most
      important line treatment for hyperinsulinemic PCOS women. Metformin is able to produce
      favourable outcomes on the metabolic derangements in insulin-resistant normal weight and
      obese PCOS patients. Oral contraceptives represent the traditional medical therapy for the
      long-term treatment of PCOS women, in order to obtain regular menstrual cycles and to improve
      the clinical signs of hyperandrogenism.Based on the above mentioned evidences, the aim of the
      present study was to evaluate the effects of DRPS/EE alone versus metformin alone versus
      DRPS/EE plus metformin on the CD4+CD28null T cells frequency and on endocrino-metabolic
      parameters, in hyperinsulinemic PCOS patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+CD28null frequency</measure>
    <time_frame>five minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the area under the curve for insulin (AUCi) and lipid profile.</measure>
    <time_frame>120 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>31 subjects were randomized to receive 500 mg Metformin per 3/die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03 mg EE plus 3 mg of DRPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin plus Yasmin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500 mg of Metformin per 3/die</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yasmin;</intervention_name>
    <description>1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)</description>
    <arm_group_label>0.03 mg EE plus 3 mg of DRPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus Yasmin</intervention_name>
    <description>0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily</description>
    <arm_group_label>Metformin plus Yasmin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-35

          -  hyperinsulinemic PCOS

        Exclusion Criteria:

          -  chronic or acute inflammatory disease, cancer, autoimmune disease, treatment with
             clomiphene citrate, oral contraceptives, antiandrogens, drugs to control appetite or
             insulin-sensitizing drugs (metformin, pioglitazone and rosiglitazone) during the last
             6 months prior to our evaluation, DM2, hypertension, major surgery in the last 3
             months or other hormonal dysfunctions (hypothalamic, pituitary, thyroidal, or adrenal
             causes).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Niccoli G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Bac√† M, Pazzano V, Gangale MF, Tropea A, Crea F. CD4+CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril. 2011 Jun 30;95(8):2651-4. doi: 10.1016/j.fertnstert.2011.01.129. Epub 2011 Feb 16.</citation>
    <PMID>21324454</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Rosanna Apa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

